Does cefdinir treat E. coli infections?
Yes. Ceftdinir (an oral cephalosporin antibiotic) can have activity against some strains of Escherichia coli (E. coli). How well it works depends on the specific E. coli strain and the infection site.
When is cefdinir likely to work for E. coli?
Cefdinir is sometimes used for infections where E. coli is a likely cause, such as certain community-acquired urinary tract infections (UTIs) or other bacterial infections. Choice depends on local resistance patterns and whether the bacteria are susceptible to cefdinir.
When might cefdinir not cover E. coli?
Cefdinir may not be effective if the E. coli strain is resistant. Resistance is common with some mechanisms, including extended-spectrum beta-lactamases (ESBL-producing strains) and other resistant gram-negative bacteria. In those cases, clinicians often choose a different antibiotic based on urine/blood culture results and susceptibility testing.
How do you know if the E. coli is susceptible?
A culture with an antibiotic susceptibility (“susceptibility testing” or “AST”) result is the best way to confirm whether that particular E. coli isolate is susceptible to cefdinir. Without those results, clinicians rely on the suspected infection source and local antibiograms.
What should you do if you were prescribed cefdinir for suspected E. coli?
If symptoms don’t improve within about 48–72 hours, or you’re getting worse (fever, flank pain, vomiting, worsening urinary symptoms), contact the prescriber promptly. They may want a culture and to switch therapy if the bacteria are resistant.
Are there better options than cefdinir for UTIs caused by E. coli?
Often, yes. For many uncomplicated UTIs, clinicians may prefer antibiotics with higher reliability against local E. coli resistance patterns and confirmed susceptibility. The right choice depends on culture results, kidney function, pregnancy status, drug allergies, and whether the infection is complicated.
If you share what infection you’re treating (UTI vs. something else) and whether you have a culture/susceptibility report, I can interpret what it suggests about cefdinir coverage.